John Militello

Chief Financial Officer, Quince Therapeutics, Inc.

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

John Militello has been Chief Financial Officer of Quince Therapeutics, Inc. since not stated, according to the company's filing of July 31, 2026.¹

The filing gives John Militello's previous role as Head of Finance at Orphai Therapeutics, LLC.¹ John Militello already worked at Quince Therapeutics, Inc. when appointed, so the record counts the move as an internal promotion.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Quince Therapeutics, Inc. (QNCX) Biological Products, (No Diagnostic Substances)	Chief Financial Officer	In the seat	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

Date not statedfiled July 31, 2026
Quince Therapeutics, Inc. appointed John Militello as Chief Financial Officer, with an effective date the filing does not state.
John Militello, CPA , age 52, was conditionally appointed as the Company’s Chief Financial Officer and will serve as the Company’s Principal Financial Officer and Principal Accounting Officer upon his appointment.
[1] Filing by Quince Therapeutics, Inc., filed with the SEC on July 31, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, Quince Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 31, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or John Militello wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.